ResMed Stock Is S&P 500’s Worst Performer. GLP-1 Drugs Are a Risk.
Wolfe Research downgraded shares of the maker of sleep-apnea airway machines to Underperform from Peer Perform.
Why ResMed's Rally Is Just Getting Started
ResMed's AirSense 11 platform and myAir app enhance patient engagement and efficiency. Check out why I remain bullish on RMD ...
ResMed Faces Market Disruption and Limited Growth: A Sell Rating Analysis
Wolfe Research analyst Michael Polark downgraded the rating on Resmed (RMD – Research Report) to a Sell yesterday, setting a price target ...
Top Stock Movers Now: US Steel, VF Corp., ResMed, and More
Major U.S. indexes were little changed at midday Wednesday, ahead of the Federal Reserve's decision on interest rates.
ResMed: Growing Returns With Continuous Acquisitions Led To A Margin Of Safety
ResMed achieved double-digit revenue growth through acquisitions and operating efficiencies, with improving capital ...
Baird给予ResMed股票"跑赢大市"评级，称其处于稳定的中单位数增长市场
周二，Baird对全球持续气道正压通气(CPAP)市场领导者ResMed (NYSE:RMD)的股票启动覆盖，给予"跑赢大市"评级，目标价为$280。 该公司的分析表明，ResMed战略性地定位于从CPAP设备市场渗透率增长中受益，这是一个稳定的中单位数增长市场。 尽管缺乏与竞争对手召回相关的市场份额增长和定价利好，但Baird预计ResMed将保持中单位数到高单位数的收入增长和低双位数到中十几位 ...
ResMed Inc. (NYSE:RMD) is a favorite amongst institutional investors who own 74%
To get a sense of who is truly in control of ResMed Inc. ( NYSE:RMD ), it is important to understand the ownership structure ...